These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23054215)

  • 21. Differential cancer predisposition in Lynch syndrome: insights from molecular analysis of brain and urinary tract tumors.
    Gylling AH; Nieminen TT; Abdel-Rahman WM; Nuorva K; Juhola M; Joensuu EI; Järvinen HJ; Mecklin JP; Aarnio M; Peltomäki PT
    Carcinogenesis; 2008 Jul; 29(7):1351-9. PubMed ID: 18550572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequent mismatch-repair defects link prostate cancer to Lynch syndrome.
    Dominguez-Valentin M; Joost P; Therkildsen C; Jonsson M; Rambech E; Nilbert M
    BMC Urol; 2016 Mar; 16():15. PubMed ID: 27013479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risks of Lynch syndrome cancers for MSH6 mutation carriers.
    Baglietto L; Lindor NM; Dowty JG; White DM; Wagner A; Gomez Garcia EB; Vriends AH; ; Cartwright NR; Barnetson RA; Farrington SM; Tenesa A; Hampel H; Buchanan D; Arnold S; Young J; Walsh MD; Jass J; Macrae F; Antill Y; Winship IM; Giles GG; Goldblatt J; Parry S; Suthers G; Leggett B; Butz M; Aronson M; Poynter JN; Baron JA; Le Marchand L; Haile R; Gallinger S; Hopper JL; Potter J; de la Chapelle A; Vasen HF; Dunlop MG; Thibodeau SN; Jenkins MA
    J Natl Cancer Inst; 2010 Feb; 102(3):193-201. PubMed ID: 20028993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands.
    Capelle LG; Van Grieken NC; Lingsma HF; Steyerberg EW; Klokman WJ; Bruno MJ; Vasen HF; Kuipers EJ
    Gastroenterology; 2010 Feb; 138(2):487-92. PubMed ID: 19900449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term risk of colorectal cancer in individuals with lynch syndrome: a meta-analysis.
    Jenkins MA; Dowty JG; Ait Ouakrim D; Mathews JD; Hopper JL; Drouet Y; Lasset C; Bonadona V; Win AK
    J Clin Oncol; 2015 Feb; 33(4):326-31. PubMed ID: 25534380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Commentary on "Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome." Win AK, Lindor NM, Young JP, Macrae FA, Young GP, Williamson E, Parry S, Goldblatt J, Lipton L, Winship I, Leggett B, Tucker KM, Giles GG, Buchanan DD, Clendenning M, Rosty C, Arnold J, Levine AJ, Haile RW, Gallinger S, Le Marchand L, Newcomb PA, Hopper JL, Jenkins MA, Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, Melbourne School of Population Health, The University of Melbourne, Victoria, Australia: J Natl Cancer Inst 2012;104(18):1363-72 [Epub 2012 Aug 28].
    See WA
    Urol Oncol; 2013 Jul; 31(5):716. PubMed ID: 23796201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of Lynch syndrome in consecutive patients with colorectal cancer.
    Green RC; Parfrey PS; Woods MO; Younghusband HB
    J Natl Cancer Inst; 2009 Mar; 101(5):331-40. PubMed ID: 19244167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium.
    Goecke T; Schulmann K; Engel C; Holinski-Feder E; Pagenstecher C; Schackert HK; Kloor M; Kunstmann E; Vogelsang H; Keller G; Dietmaier W; Mangold E; Friedrichs N; Propping P; Krüger S; Gebert J; Schmiegel W; Rueschoff J; Loeffler M; Moeslein G;
    J Clin Oncol; 2006 Sep; 24(26):4285-92. PubMed ID: 16908935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer.
    Lu KH; Schorge JO; Rodabaugh KJ; Daniels MS; Sun CC; Soliman PT; White KG; Luthra R; Gershenson DM; Broaddus RR
    J Clin Oncol; 2007 Nov; 25(33):5158-64. PubMed ID: 17925543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
    Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
    Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic immunohistochemical screening for Lynch syndrome in colorectal cancer: a single centre experience of 486 patients.
    Zumstein V; Vinzens F; Zettl A; Heinimann K; Koeberle D; von Flüe M; Bolli M
    Swiss Med Wkly; 2016; 146():w14315. PubMed ID: 27152634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lynch syndrome in urological practice: diagnosis, therapeutic strategies, and screening for upper tract urothelial carcinoma.
    Lonati C; Moschini M; Simeone C; Spiess PE; Necchi A
    Curr Opin Urol; 2022 Jan; 32(1):40-47. PubMed ID: 34608026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Excess of extracolonic non-endometrial multiple primary cancers in MSH2 germline mutation carriers over MLH1.
    Lin-Hurtubise KM; Yheulon CG; Gagliano RA; Lynch HT
    J Surg Oncol; 2013 Dec; 108(7):433-7. PubMed ID: 24122742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members.
    Järvinen HJ; Renkonen-Sinisalo L; Aktán-Collán K; Peltomäki P; Aaltonen LA; Mecklin JP
    J Clin Oncol; 2009 Oct; 27(28):4793-7. PubMed ID: 19720893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United States.
    Kastrinos F; Stoffel EM; Balmaña J; Steyerberg EW; Mercado R; Syngal S
    Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):2044-51. PubMed ID: 18708397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree.
    Wagner A; Hendriks Y; Meijers-Heijboer EJ; de Leeuw WJ; Morreau H; Hofstra R; Tops C; Bik E; Bröcker-Vriends AH; van Der Meer C; Lindhout D; Vasen HF; Breuning MH; Cornelisse CJ; van Krimpen C; Niermeijer MF; Zwinderman AH; Wijnen J; Fodde R
    J Med Genet; 2001 May; 38(5):318-22. PubMed ID: 11333868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mismatch repair gene mutation analysis and colonoscopy surveillance in Chinese Lynch syndrome families.
    Fu L; Sheng JQ; Li XO; Jin P; Mu H; Han M; Huang JS; Sun ZQ; Li AQ; Wu ZT; Li SR
    Cell Oncol (Dordr); 2013 Jun; 36(3):225-31. PubMed ID: 23640085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer Risk in Families Fulfilling the Amsterdam Criteria for Lynch Syndrome.
    Samadder NJ; Smith KR; Wong J; Thomas A; Hanson H; Boucher K; Kopituch C; Cannon-Albright LA; Burt RW; Curtin K
    JAMA Oncol; 2017 Dec; 3(12):1697-1701. PubMed ID: 28772302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer risks and immunohistochemical profiles linked to the Danish MLH1 Lynch syndrome founder mutation.
    Therkildsen C; Isinger-Ekstrand A; Ladelund S; Nissen A; Rambech E; Bernstein I; Nilbert M
    Fam Cancer; 2012 Dec; 11(4):579-85. PubMed ID: 22864660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer-risk by family history and mismatch-repair mutation in Lynch syndrome.
    Marques-de-Sá I; Castro R; Pita I; Dinis-Ribeiro M; Brandão C
    Scand J Gastroenterol; 2020 Jun; 55(6):701-705. PubMed ID: 32448028
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.